Fate Therapeutics, Inc. (NASDAQ:FATE) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2017, Fate Therapeutics, Inc. (the Company) issued a
press release announcing its financial results for the quarter
ended March 31, 2017. A copy of the press release is attached as
Exhibit 99.1.
The information in this Item 2.02 of this Current Report on Form
8-K, including Exhibit 99.1, is being furnished and shall not be
deemed filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (Exchange Act) or otherwise
subject to the liability of that section, nor shall such
information be deemed incorporated by reference in any filing
under the Exchange Act or the Securities Act of 1933, as amended,
regardless of the general incorporation language of such filing,
except as shall be expressly set forth by specific reference in
such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release dated May 15, 2017 |
About Fate Therapeutics, Inc. (NASDAQ:FATE)
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics, Inc. (NASDAQ:FATE) Recent Trading Information
Fate Therapeutics, Inc. (NASDAQ:FATE) closed its last trading session up +0.10 at 4.11 with 87,151 shares trading hands.
